相关实验视频
Updated: Jun 24, 2025

06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
7.7K
心脏 Amyloidosis 的标准疗法: 已知,什么是"灰色"
Annamaria Del Franco1, Giulia Biagioni1, Carlotta Mazzoni1
1Cardiomyopathy Division, Careggi University Hospital, Aou Careggi, Largo Brambilla 3, Florence 50134, Italy.
Heart failure clinics
|June 6, 2024
概括
氨基粉症会损害心脏,往往导致心力衰竭 (HF). 早期诊断心肌粉症 (CA) 通过及时干预和更好的管理策略来改善患者的结果.
科学领域:
- 心脏病学 心脏病学
- 系统性疾病 系统性疾病
- 医学诊断 医学诊断 医学诊断
背景情况:
- 粉样性粉症是一种全身性疾病,其特征是错误折叠的粉样纤维的积累.
- 心脏粉症 (CA) 严重损害了心脏,使患者的预后恶化.
- 心力衰竭 (HF) 是晚期氨基粉症的常见表现和诊断指标.
研究的目的:
- 审查心力衰竭和心脏粉症患者的关键临床管理问题.
- 强调早期诊断的重要性,以改善心脏粉症的自然过程.
- 为突出认识到和管理心脏粉样化症的进步.
主要方法:
- 对心脏粉症的临床管理策略的文献综述.
- 对心力衰竭患者的诊断标准和预后因素的分析.
- 综合目前关于早期诊断对心脏氨基粉症进展的影响的研究.
主要成果:
- 早期诊断心脏氨基粉症是可以实现和至关重要的.
- 更好地了解心脏氨基粉症,可以更好地管理患者.
- 及时干预可以积极影响疾病的自然进程.
结论:
- 在心力衰竭患者中识别心脏氨基粉症至关重要.
- 提高诊断意识可以改善治疗策略.
- 积极主动地治疗心脏粉症可以减轻心脏损伤并改善结果.
相关概念视频
Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179

